What LIVISTO does

LIVISTO (legal entity: INDUSTRIA ITALIANA INTEGRATORI TREI S.p.A.) is an Italian-headquartered animal health company that develops, manufactures, and commercializes veterinary pharmaceuticals and nutritional products for both livestock (cattle, pigs, poultry, sheep/goats, horses) and companion animals (dogs, cats, horses). The company emerged from the merger of aniMedica, Invesa, Lhisa, and Trei and operates under the direction of German agricultural conglomerate AGRAVIS Raiffeisen AG, which acts as its parent. Its portfolio is anchored by proprietary delivery and formulation technologies, including the BIOPASS rumen-bypass protection system that shields active ingredients from rumen degradation, the patented TricoStimulant agro-technology (partnered with Biotech Tricopharming Research) used in the Artennua Artemisia annua-based complementary feed, and the PetCellPen cold atmospheric plasma device for veterinary dermatology. The product range spans dermatology (V-SKIN line), pain management (Hyalutidin, Hedylon, Prednisolone), internal medicine (Metrovis), dentistry (DENTISEPT, Dentihex), antiparasitics (Deltatic collar), wound care (ALUMAX), and a dedicated equine line (Derbymed).

LIVISTO generates revenue through a B2B2C veterinary distribution model: pharmaceutical and nutritional products flow through veterinary clinics, veterinary pharmacies, and distributors, with veterinarians as the primary prescribing touchpoint. Pricing is not publicly disclosed, and product catalogs are gated to registered veterinary professionals. The company runs an Italian field sales force and an extensive event-driven marketing program spanning national veterinary congresses (SCIVAC, SIDEV, UNISVET), international trade fairs, in-clinic SpritzVet training evenings, consumer-facing events such as ZampaFest, and dedicated digital platforms including the Livisto In-Practice e-learning site and the HappyVet Project veterinarian well-being platform. Operationally, LIVISTO is a member of Access VetMed (formerly EGGVP), a network of 25 European generic veterinary pharmaceutical companies across 31 EU countries that collectively hold 45% of EU generic veterinary marketing authorizations, and has expanded internationally with country operations in Germany, Spain, Poland, Russia, Guatemala (LIVISTO Guatemala S.A., acquired January 2023), El Salvador, and Thailand.

Name

LIVISTO

Legal name

INDUSTRIA ITALIANA INTEGRATORI TREI S.p.A.

Website

https://livisto.it

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

LIVISTO is an Italian animal health company (part of AGRAVIS Raiffeisen AG) that develops and markets veterinary pharmaceuticals and nutritional products for livestock and companion animals, distributed through veterinarians, pharmacies, and its own field sales force across Europe, Central America, and Asia.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Animal Food Manufacturing (3111)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Dermatology & Allergy Drugs (HLAMAEAH), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF), Species-Specific Supplements (Dog/Cat/Other Companion Species) (HLAMALAN)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Livestock medications
• Companion animal nutrition
• Veterinary dermocosmetics

Headquarters

HQ city

Rio Saliceto

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Products: LIVISTO develops, manufactures, and commercializes veterinary pharmaceutical products for the treatment and prevention of diseases in livestock (mastitis, metabolic disorders, respiratory diseases, digestive problems, deficiencies) and companion animals (dermatology, pain therapy, internal medicine). Revenue is generated through direct sales to veterinarians and distribution through veterinary pharmacies.
2. Nutritional / Nutraceutical Products: LIVISTO commercializes nutritional products, dietary feeds, and nutraceuticals (e.g., Hyalutidin chondroprotective syrup, Hemdiol Flex for osteoarthritis, feed additives with BIOPASS rumen bypass technology) targeting both livestock farmers and companion animal owners through veterinarians.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

LIVISTO develops, manufactures, and commercializes veterinary pharmaceutical and nutritional products for both livestock animals (cattle, pigs, poultry, sheep/goats, horses) and companion animals (dogs, cats). Its portfolio spans therapeutic treatments (mastitis, respiratory and metabolic disorders, dermatology, pain therapy, internal medicine, parasitology, dentistry) and nutritional supplements, including proprietary technologies such as the BIOPASS rumen bypass system, V-SKIN dermocosmetic line, and Petcellpen cold plasma device. Products are sold to veterinarians, veterinary pharmacies, distributors, livestock farmers, and through dedicated consumer e-commerce sites for select brands.

Product overview

LIVISTO is an animal health company developing, producing, and commercializing pharmaceutical and nutritional products. The portfolio is organized across two main segments: Livestock Animals (cattle, pigs, poultry, sheep/goats, horses) and Companion Animals (dogs, cats, horses). For livestock, key therapeutic areas include mastitis, metabolic disorders, respiratory diseases, digestive problems, and nutritional deficiencies, with specialized technology like BIOPASS rumen bypass. For companion animals, offerings span dermatology (V-SKIN dermocosmetics, Petcellpen cold plasma), pain therapy (Hyalutidin chondroprotector, Prednisolone, Hedylon), internal medicine (Metrovis), dentistry (DENTISEPT, Dentihex), and antiparasitics (Deltatic collar, Artennua). The company also provides educational platforms including Livisto In-Practice e-learning and HappyVetProject wellness resources for veterinarians.

Differentiator

Problem solved

Functional benefit

Brands

• Deltatic: Deltamethrin-based collar product line for fleas, ticks, mosquitoes and sandflies, providing protection against leishmaniasis transmission
• Dentihex
• V-SKIN
• Derbymed

Products and services

• V-SKIN Dermocosmetic Line Dermocosmetic product line for dogs and cats developed with veterinary dermatology experts, covering ear cleaning, atopic skin, seborrheic conditions, and wound care. Marketed to veterinarians and pet owners via a dedicated consumer website (v-skin.pet).
• ALUMAX SPRAY Multispecies wound healing spray based on colloidal aluminum that promotes wound healing and reduces infection risk in animals. Positioned as a post-operative protective barrier.
• Deltatic Deltamethrin-based collar product for dogs providing protection against fleas, ticks, mosquitoes, and sandflies (phlebotomines), including Leishmaniasis prevention. Marketed to veterinarians and pet owners via a dedicated consumer website.
• Dentihex Dental hygiene product for companion animals (dogs and cats), sold through a dedicated consumer website (dentihex.pet).
• Derbymed Horse health product line covering respiratory, articular, gastrointestinal, reproductive, recovery, sport, hoof, skin and coat areas, with preventive and therapeutic solutions for equine care.
• Artennua Complementary feed for dogs and cats based on optimized Artemisia annua extract, rich in artemisinin and flavonoids, used to support immune function and Leishmaniasis management. Distributed under a partnership with Biotech Tricopharming Research.
• Hemdiol Flex Dietary food for dogs supporting osteoarthritis management, formulated with cold-pressed hemp flour, Omega3, EPA, and Curcumin as a non-GMO natural nutraceutical.
• Metrovis Metronidazole product (Easy-tab) available in 100mg, 250mg, and 750mg divisible beef-flavored, allergen-free tablets for the treatment of gastrointestinal disorders in dogs and cats.
• Prednisolone Corticosteroid tablets in 5mg and 25mg concentrations for symptomatic treatment of inflammatory and immune-mediated diseases in dogs and cats.
• Hedylon Anti-inflammatory product referenced in LIVISTO's dermatology treatment portfolio for dogs.
• Hyalutidin / Hyalutidind dc Chondroprotective complementary feed syrup for dogs, positioned as the only highly bioavailable syrup form of hyaluronic-acid-based joint support available on the Italian market.
• Petcellpen Innovative cold atmospheric plasma (CAP) device for veterinary dermatology applications, marketed to veterinary clinics as a clinical device for skin treatments in companion animals.
• DENTISEPT Adhesive dental paste for veterinary dentistry, positioned as the only product of its kind available on the Italian market.

Quantifiable outcome

• Over 350 veterinarians gathered at SIDEV congress 2025 to discuss canine atopic dermatitis, with LIVISTO presenting V-SKIN and PetCellPen products.
• +3 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered regional, core and minor.

• Servi Agro (now LIVISTO Guatemala S.A.)regionalChannel Partner/ Reseller/ Distributor · 1 January 2023LIVISTO acquired the activities of its long-standing Guatemalan distributor Servi Agro through a new group company, LIVISTO Guatemala S.A., effective January 1, 2023. The acquisition extends LIVISTO's presence in Central America, building on over 20 years of prior distribution relationship. Guatemala is a strategically important market with the largest territorial extension and high demographic concentration in the region.
• Access VetMed (formerly EGGVP)coreStrategic or Co-development PartnerLIVISTO is a member of Access VetMed, a European group of 25 generic veterinary medicine companies operating in 31 EU countries, with over 7,600 employees and holding 45% of all EU generic veterinary medicine marketing authorizations. The group advocates for sustainable veterinary medicine policies and generic veterinary product access across Europe.
• Biotech Tricopharming ResearchcoreTechnology or IntegrationLIVISTO partners with Biotech Tricopharming Research, a Spanish company specializing in optimization and standardization of botanical ingredients using green biotechnologies. LIVISTO distributes Artennua in Italy, a complementary feed for dogs and cats derived from optimized Artemisia annua extract produced using Tricopharming's proprietary TricoStimulant patented technology.
• Hill's Pet NutritionminorGTM or Marketing PartnerLIVISTO co-sponsored the SpritzVet veterinary educational evening in Milan with Hill's Pet Nutrition, combining LIVISTO's dermatology products with Hill's nutritional offerings in a collaborative educational format for veterinarians.
• VetPartners ItaliaminorStrategic or Co-development PartnerLIVISTO collaborates with VetPartners Italia, a major veterinary corporate group, to provide clinical information and support case management for practicing veterinarians. The collaboration focuses on sharing knowledge and best clinical practices, including feline asthma management protocols.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vetoquinol: Independent French veterinary pharmaceutical company with comparable scale (~$500M revenue) and a broad livestock + companion animal portfolio. Highly comparable on product mix (livestock therapeutics, pet dermatology, nutraceuticals) and European mid-market positioning.
• Virbac: French independent veterinary pharma with global presence across livestock and companion animals. Direct competition in dermatology, parasitology, and nutraceutical categories where LIVISTO operates (V-SKIN, Deltatic, Artennua).
• Ceva Santé Animale: French veterinary pharmaceutical group with comparable livestock + companion animal portfolio and European + emerging market footprint. Competes across many of LIVISTO's therapeutic categories and benefits from similar pan-European distribution scale.
• Dechra Pharmaceuticals: UK-based veterinary pharma specialist focused on companion animal endocrinology, dermatology, and pain management — overlapping directly with LIVISTO's V-SKIN, Hedylon/Prednisolone, and Hyalutidin product lines. Acquired by Elanco in 2024 but historically a direct independent peer.
• Laboratorios Calier: Spanish veterinary pharmaceutical company with similar livestock + companion animal portfolio and Iberian/European geographic footprint. Comparable mid-market size and product breadth, especially in biologicals and farm animal therapeutics.
• Hipra: Spanish veterinary biologics and pharmaceutical company with strong livestock vaccine and antimicrobial portfolio. Comparable European mid-market veterinary pharma positioning and focus on farm animal Rx where LIVISTO competes.
• Norbrook Laboratories: UK/Northern Ireland-based veterinary pharmaceutical manufacturer with comparable focus on generic livestock and companion animal therapeutics. Similar mid-market positioning, product breadth, and European distribution model.

Broad incumbents

• Zoetis: World's largest animal health company with comprehensive livestock and companion animal portfolio. Sets the competitive benchmark across virtually all of LIVISTO's therapeutic categories and has substantially greater R&D and marketing scale.
• Boehringer Ingelheim Animal Health: Top-3 global animal health player with strong livestock vaccines, parasiticides, and companion animal therapeutics. Competes with LIVISTO across farm animal (respiratory, metabolic) and pet dermatology/pain categories.
• Elanco Animal Health: Global animal health incumbent with broad livestock + companion animal portfolio including the recently acquired Dechra. Competes across LIVISTO's full product spectrum and owns higher-profile companion animal dermatology brands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/livistogroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LIVISTO